AxoGen, Inc. (NASDAQ:AXGN) – Equities research analysts at Wedbush decreased their Q3 2017 EPS estimates for AxoGen in a research note issued on Thursday. Wedbush analyst Levy. T now expects that the medical equipment provider will post earnings per share of ($0.10) for the quarter, down from their prior estimate of ($0.09). Wedbush currently has a “Outperform” rating and a $14.00 price objective on the stock. Wedbush also issued estimates for AxoGen’s Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.42) EPS, FY2018 earnings at ($0.22) EPS and FY2019 earnings at $0.10 EPS.

AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The firm had revenue of $15.20 million during the quarter, compared to the consensus estimate of $14.40 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue was up 46.2% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/07/q3-2017-earnings-estimate-for-axogen-inc-issued-by-wedbush-axgn.html.

A number of other research analysts also recently issued reports on AXGN. ValuEngine upgraded AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald started coverage on AxoGen in a research note on Thursday, June 29th. They set an “overweight” rating and a $18.00 price target on the stock. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, Leerink Swann started coverage on AxoGen in a research note on Monday, July 31st. They set an “outperform” rating and a $22.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $15.90.

Shares of AxoGen (AXGN) opened at 14.65 on Monday. AxoGen has a 12-month low of $6.51 and a 12-month high of $17.25. The company’s 50 day moving average price is $15.87 and its 200-day moving average price is $12.68. The firm’s market cap is $486.97 million.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in AxoGen by 12.8% in the fourth quarter. State Street Corp now owns 352,735 shares of the medical equipment provider’s stock worth $3,175,000 after buying an additional 39,963 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in AxoGen by 17.3% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 19,903 shares of the medical equipment provider’s stock worth $179,000 after buying an additional 2,935 shares during the last quarter. AQR Capital Management LLC bought a new stake in AxoGen during the fourth quarter worth $180,000. Teachers Advisors LLC boosted its stake in AxoGen by 25.5% in the fourth quarter. Teachers Advisors LLC now owns 48,740 shares of the medical equipment provider’s stock worth $439,000 after buying an additional 9,893 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in AxoGen by 978.5% in the first quarter. Bank of Montreal Can now owns 14,981 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 13,592 shares during the last quarter. Hedge funds and other institutional investors own 64.58% of the company’s stock.

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.